<DOC>
	<DOC>NCT00841113</DOC>
	<brief_summary>To compare the safety of efficacy of abarelix versus goserelin plus bicalutamide in patients with advanced or metastatic prostate cancer.</brief_summary>
	<brief_title>Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer</brief_title>
	<detailed_description>Inclusion Criteria - Males over 18 with documented advanced or metastatic prostate cancer Outcome measures - Comparative castration rates one week after starting therapy - Degree of testosterone surge in the first month of treatment. - Maintenance of medical castration during one year of therapy. - Comparison of the treatments on QTc prolongation</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Abarelix</mesh_term>
	<criteria>Histologically proven prostate cancer and not previously treated with hormones Evidance of advanced disease or metastases Life expentancy of at least 3 months Normal serum testosterone levels Written informed consent Previous endocrine or cytoxic theapy for prostate cancer Known tumour complication of prostate cancer which owuld require immediate treatment Another malignancy other than basal cell cancer History of significant drug hypersensitivity to either LHRH agonists or GnRH antagonists. Congenital or acquired coagulation disorders contraindicating intramuscular injections Pagets disease of the bone QTcB &gt; 450 msec at Day 14</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Advanced</keyword>
	<keyword>Metastatic</keyword>
</DOC>